Last reviewed · How we verify
Cohort C: bevacizumab
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A).
Bevacizumab is a monoclonal antibody that inhibits angiogenesis by binding to vascular endothelial growth factor A (VEGF-A). Used for Metastatic colorectal cancer, Metastatic non-small cell lung cancer, Metastatic renal cell carcinoma.
At a glance
| Generic name | Cohort C: bevacizumab |
|---|---|
| Sponsor | PPD Development, LP |
| Drug class | Angiogenesis inhibitor |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By binding to VEGF-A, bevacizumab prevents the formation of new blood vessels, thereby inhibiting tumor growth and metastasis. This mechanism is particularly effective in treating cancers that are highly vascularized.
Approved indications
- Metastatic colorectal cancer
- Metastatic non-small cell lung cancer
- Metastatic renal cell carcinoma
- Epithelial ovarian cancer
- Glioblastoma
Common side effects
- Hypertension
- Nausea
- Fatigue
- Headache
- Rash
Key clinical trials
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record) (PHASE2)
- JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab (PHASE2)
- Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors (PHASE1)
- EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (EARLY_PHASE1)
- A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation (PHASE1)
- Study of INCB123667 in Subjects With Advanced Solid Tumors (PHASE1)
- Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cohort C: bevacizumab CI brief — competitive landscape report
- Cohort C: bevacizumab updates RSS · CI watch RSS
- PPD Development, LP portfolio CI